Metformin induced Bullous pemphigoid - A Rare Case Report

Authors

  • Nitesh R. Pokharel Consultant Dermatologist

DOI:

https://doi.org/10.66344/jpad.31.4.2021.1780

Abstract

Bullous Pemphigoid(BP) is a chronic, acquired autoimmune skin disease. Exact etiology of this autoimmune process is not known. Certain drugs such as furosemide, penicillins, sulfonamides, ciprofloxacin, penicillamines, Angiotensin Converting Enzyme(ACE) inhibitors, chloroquine,etanercept,  and phenacetin were reported to cause BP. Metformin is also a rarer one to cause BP. This is a case report of a 58-year-old female recently diagnosed with Type 2 Diabetes Mellitus(T2DM), started on Metformin, presented with the formation of few cutaneous tense bullae on both distal forearm. Clinical finding of skin lesions and direct immunofluorescence (DIF) finding were consistent with BP. To our best knowledge, this is among the very few cases of Metformin induced BP in the literature.

Downloads

Published

2022-03-29

How to Cite

1.
Pokharel NR. Metformin induced Bullous pemphigoid - A Rare Case Report. J Pak Assoc Dermatol [Internet]. 2022Mar.29 [cited 2026Apr.22];31(4):740-3. Available from: https://www.jpad.com.pk/index.php/jpad/article/view/1780

Issue

Vol. 31 No. 4 (2021): October - December

Section

Case Reports

License

Submission declaration

Authors retain the copyright to their work and grant the 'Journal of Pakistan Association of Dermatologists (JPAD)' the right of first publication under a Creative Commons Attribution 4.0 International (CC BY 4.0) license. This license allows others to share, adapt, and reuse the work for any purpose, including commercial use, as long as appropriate credit is given to the original authors and the journal.

By submitting a manuscript, authors confirm that the work has not been published previously (except as an abstract, lecture, or academic thesis), is not under review elsewhere, and has been approved by all authors and relevant authorities. Once accepted, the article will be openly accessible under the CC BY 4.0 license, ensuring wide dissemination and reuse with proper attribution.